Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GFH276 Combined With Cetuximab or Chemotherapy in Solid Tumors and PDAC Harboring RAS Mutation
NCT07678593Phase 2Recruiting
- Sponsor
- GenFleet Therapeutics
- Start
- Sep 2026
- Primary completion
- Nov 2027
- Countries
- 2
01
Overview
A Phase 2 trial of GFH276 in solid tumor, pancreatic ductal adenocarcinoma (PDAC), sponsored by GenFleet Therapeutics. Started Sep 2026; status: recruiting.
02
Drugs
GFH276
03
Conditions
solid tumorpancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07678593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07678593.